Actively Recruiting
Comparing OxiblumeCoQ10 Ralivia and Placebo for Benign Prostatic Hyperplasia in Men Ages 50 to 80
Led by G.Gennimatas General Hospital · Updated on 2026-06-10
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the treatment efficacy and safety of OxiblumeCoQ10 Ralivia therapy compared to a placebo in men diagnosed with benign prostatic hyperplasia BPH. This randomized, double-blind, placebo-controlled clinical trial involves men aged 50 to 80 years with specific prostate symptom scores and urinary flow measurements. The study is coordinated by the 1st Urology Department at G. Gennimatas Hospital, Greece. Participants are assigned to one of two groups the active treatment group will take one pill of Ralivia daily for three months, while the placebo group will take a matching placebo pill daily over the same period. The trial includes evaluations at 6 and 12 weeks after starting treatment, including symptom questionnaires, ultrasounds of the prostate and urinary bladder, uroflowmetry, and blood tests measuring PSA and inflammatory markers. During the study, participants will complete symptom and erectile function questionnaires and undergo prostate and bladder ultrasounds before and after voiding, alongside uroflowmetry tests at the scheduled visits. Blood samples will assess PSA, TNFa, and interleukins at 6 and 12 weeks. Adverse events will be monitored throughout the trial. The primary outcome is the change in International Prostate Symptom Score IPSS after 12 weeks of treatment.
CONDITIONS
Brief Title
Oxiblume:CoQ10 (Ralivia) Therapy for Benign Prostatic Hyperplasia:
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
